Cypherpunk is a biopharmaceutical company developing antibody therapies for cancer while executing a digital-asset treasury strategy.
Cypherpunk Technologies (formerly Leap Therapeutics) has raised $58.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Cypherpunk Technologies (formerly Leap Therapeutics)'s investors include Gilead Sciences, Samsara BioCapital, BeiGene, Winklevoss Capital, Rock Springs Capital.
Cypherpunk Technologies (formerly Leap Therapeutics) is headquartered in Cambridge, United States.
Cypherpunk is a biopharmaceutical company developing antibody therapies for cancer while executing a digital-asset treasury strategy.
Cypherpunk Technologies (formerly Leap Therapeutics) is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cypherpunk Technologies (formerly Leap Therapeutics) — Funding & Investors." VCBacked, October 6, 2025, https://www.vcbacked.co/company/cypherpunk-technologies-formerly-leap-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Cypherpunk Technologies (formerly Leap Therapeutics) — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cypherpunk-technologies-formerly-leap-therapeutics
{{cite web |title=Cypherpunk Technologies (formerly Leap Therapeutics) — Funding & Investors |url=https://www.vcbacked.co/company/cypherpunk-technologies-formerly-leap-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated